REMARKS

Applicants elect for further examination the claims of Group II, claims 9, 10, 16 and 17, drawn to a compound having a phenanthridine ring or a pharmaceutical composition thereof. Applicants make the election without traverse, and without prejudice to a request for rejoinder and/or pursuit of non-elected claims in related applications.

Applicants elect the species spongiform encephalopathy. Claims 9, 10, 16 and 17 are readable on the species.

Applicants explicitly reserve the right to rejoinder of method claims (Group IV - Claims 13 and 14) drawn to a method for treating neurodegenerative diseases involving protein aggregates by administering a compound of elected Group II.

Applicants withdraw from consideration those method claims until a compound/product claim is found allowable, at which time method claims commensurate in scope with the allowed compound/product claims can be rejoined in accordance with the provisions of MPEP 821.04.

Applicants believe that the foregoing is fully responsive to the outstanding Official Action including the restriction and the election of species requirement. If, however, the Examiner believes that any further information or election is required, the Examiner is encouraged to contact applicants' attorney at the number provided below. Such informal communication will expedite examination and disposition of the case.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: March 20, 2008

By:

Brian P. O'Shaughnessy Registration No. 32747 /

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620